The increased levels of NAMPT tissue staining (Figure 3A,B) and eNAMPT plasma levels (212 ± 25 pg/mL vs. 102 ± 0.4 pg/mL) (Figure 5B) were corroborated by Western blot analysis of liver lysates from control and STZ/HFD mice with increased NAMPT protein immunoreactivity in NAFLD hepatic tissues (Figure 5E,F). This evidence concerns the gene NAMPT and metabolic dysfunction-associated steatotic liver disease.